Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 13/20 | 0.43 |
| ▸ | GAK | O14976 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | NSD3 | Q9BZ95 | 2/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.37 |
| ▸ | MYC | P01106 | 1/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25820075 | 0.89 | CCNC (0.42) | AAK1GAK | |
| SCHEMBL26664503 | 0.81 | GABRA1 (0.47) | — | |
| SCHEMBL25820133 | 0.81 | HTR1A (0.53) | AAK1NSD3PTGER1 | |
| SCHEMBL24338479 | 0.81 | FERMT2 (0.50) | FERMT2AAK1GAKGRM4NSD3 | |
| SCHEMBL30149344 | 0.81 | FERMT2 (0.50) | FERMT2AAK1GAKGRM4NSD3 | |
| SCHEMBL30174534 | 0.77 | FERMT2 (0.50) | FERMT2AAK1GAKGRM4NSD3 | |
| SCHEMBL24338855 | 0.77 | FERMT2 (0.50) | FERMT2AAK1GAKGRM4NSD3 | |
| SCHEMBL26220553 | 0.77 | FERMT2 (0.50) | FERMT2AAK1GAKGRM4NSD3 | |
| SCHEMBL22648432 | 0.76 | FERMT2 (0.45) | FERMT2AAK1GAKGRM4NSD3 | |
| SCHEMBL2494065 | 0.75 | LOXL2 (0.58) | FERMT2AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | FERMT2 2988/4885AAK1 1644/4885GAK 505/4885 |
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | FERMT2 2751/4885AAK1 1272/4885GAK 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.